In a subsequent meta-analysis, the largest of these meta-analyses to date (n = 11,874), OS was significantly longer in female than male NSCLC patients who received EGFR TKI therapy (HR 0.86 [95% CI 0.75–1.00]; p = 0.04) [36]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.